Literature DB >> 12955177

Ventilator-associated pneumonia: caveats for benchmarking.

Philippe Eggimann1, Stéphane Hugonnet, Hugo Sax, Sylvie Touveneau, Jean-Claude Chevrolet, Didier Pittet.   

Abstract

OBJECTIVE: To determine the influence of using different denominators on risk estimates of ventilator-associated pneumonia (VAP). DESIGN AND
SETTING: Prospective cohort study in the medical ICU of a large teaching hospital. PATIENTS: All consecutive patients admitted for more than 48 h between October 1995 and November 1997. MEASUREMENTS AND
RESULTS: We recorded all ICU-acquired infections using modified CDC criteria. VAP rates were reported per 1,000 patient-days, patient-days at risk, ventilator-days, and ventilator-days at risk. Of the 1,068 patients admitted, VAP developed in 106 (23.5%) of those mechanically ventilated. The incidence of the first episode of VAP was 22.8 per 1,000 patient-days (95% CI 18.7-27.6), 29.6 per 1,000 patient-days at risk (24.2-35.8), 35.7 per 1,000 ventilator-days (29.2-43.2), and 44.0 per 1,000 ventilator-days at risk (36.0-53.2). When considering all episodes of VAP (n=127), infection rates were 27.3 episodes per 1,000 ICU patient-days (95% CI 22.6-32.1) and 42.8 episodes per 1,000 ventilator-days (35.3-50.2).
CONCLUSIONS: The method of reporting VAP rates has a significant impact on risk estimates. Accordingly, clinicians and hospital management in charge of patient-care policies should be aware of how to read and compare nosocomial infection rates.

Entities:  

Mesh:

Year:  2003        PMID: 12955177     DOI: 10.1007/s00134-003-1991-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  19 in total

Review 1.  Evidence-based assessment of diagnostic tests for ventilator-associated pneumonia. Executive summary.

Authors:  R F Grossman; A Fein
Journal:  Chest       Date:  2000-04       Impact factor: 9.410

Review 2.  Ventilator associated pneumonia: perspectives on the burden of illness.

Authors:  D Cook
Journal:  Intensive Care Med       Date:  2000       Impact factor: 17.440

Review 3.  Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1996-05       Impact factor: 21.405

4.  The risks of risk adjustment.

Authors:  L I Iezzoni
Journal:  JAMA       Date:  1997-11-19       Impact factor: 56.272

5.  Characteristics of hospitals and infection control professionals participating in the National Nosocomial Infections Surveillance System 1999.

Authors:  C Richards; T G Emori; J Edwards; S Fridkin; J Tolson; R Gaynes
Journal:  Am J Infect Control       Date:  2001-12       Impact factor: 2.918

6.  The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals.

Authors:  R W Haley; D H Culver; J W White; W M Morgan; T G Emori; V P Munn; T M Hooton
Journal:  Am J Epidemiol       Date:  1985-02       Impact factor: 4.897

7.  Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients.

Authors:  D J Cook; S D Walter; R J Cook; L E Griffith; G H Guyatt; D Leasa; R Z Jaeschke; C Brun-Buisson
Journal:  Ann Intern Med       Date:  1998-09-15       Impact factor: 25.391

8.  CDC definitions for nosocomial infections, 1988.

Authors:  J S Garner; W R Jarvis; T G Emori; T C Horan; J M Hughes
Journal:  Am J Infect Control       Date:  1988-06       Impact factor: 2.918

Review 9.  Ventilator-associated pneumonia.

Authors:  Jean Chastre; Jean-Yves Fagon
Journal:  Am J Respir Crit Care Med       Date:  2002-04-01       Impact factor: 21.405

10.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.

Authors:  J L Vincent; D J Bihari; P M Suter; H A Bruining; J White; M H Nicolas-Chanoin; M Wolff; R C Spencer; M Hemmer
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

View more
  15 in total

1.  Ventilator-associated pneumonia: caveats for benchmarking.

Authors:  J E Tulleken; J G Zijlstra; J J M Ligtenberg; R Spanjersberg; T S van der Werf
Journal:  Intensive Care Med       Date:  2004-03-24       Impact factor: 17.440

2.  Invasive devices: no need? No use!

Authors:  Stijn I Blot; Renaat Peleman; Koenraad H Vandewoude
Journal:  Intensive Care Med       Date:  2006-12-05       Impact factor: 17.440

3.  Sporadic isolations of a multi-drug resistant Pseudomonas aeruginosa clone during a 14-month epidemic in a general hospital in Hiroshima.

Authors:  S Kouda; Y Fujiue; Y Watanabe; M Ohara; S Kayama; F Kato; J Hisatsune; K Tsuruda; A Matsubara; M Doi; M Kuwabara; M Sugai
Journal:  Infection       Date:  2011-04-22       Impact factor: 3.553

4.  Prognosis and risk factors of early onset pneumonia in ventilated patients with Guillain-Barré syndrome.

Authors:  David Orlikowski; Tarek Sharshar; Raphael Porcher; Djillali Annane; Jean Claude Raphael; Bernard Clair
Journal:  Intensive Care Med       Date:  2006-09-21       Impact factor: 17.440

5.  Incidence in ICU populations: how to measure and report it?

Authors:  Jan Beyersmann; Petra Gastmeier; Martin Schumacher
Journal:  Intensive Care Med       Date:  2014-05-10       Impact factor: 17.440

6.  Severity of ICU-acquired pneumonia according to infectious microorganisms.

Authors:  Pierre Damas; Nathalie Layios; Laurence Seidel; Monique Nys; Pierrette Melin; Didier Ledoux
Journal:  Intensive Care Med       Date:  2011-05-26       Impact factor: 17.440

7.  Incidence and risk factors of device-associated infections and associated mortality at the intensive care in the Dutch surveillance system.

Authors:  Tjallie I I van der Kooi; Annette S de Boer; Judith Manniën; Jan C Wille; Mariëlle T Beaumont; Ben W Mooi; Susan van den Hof
Journal:  Intensive Care Med       Date:  2006-12-05       Impact factor: 17.440

8.  Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.

Authors:  Michael P Horn; Adrian W Zuercher; Martin A Imboden; Michael P Rudolf; Hedvika Lazar; Hong Wu; Niels Hoiby; Stefanie C Fas; Alois B Lang
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

9.  Ventilator-associated pneumonia in severe traumatic brain injury.

Authors:  David A Zygun; Danny J Zuege; Paul J E Boiteau; Kevin B Laupland; Elizabeth A Henderson; John B Kortbeek; Christopher J Doig
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

10.  Preventing ventilator-associated pneumonia: does the evidence support the practice?

Authors:  Naomi P O'Grady; Patrick R Murray; Nancy Ames
Journal:  JAMA       Date:  2012-06-20       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.